Not all selective estrogen response modulators are created equal: update on lasofoxifene.
Goldstein
S R
SR
Department of Obstetrics and Gynecology, New York University School of Medicine, New York, USA.
D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D001943:Breast Neoplasms / Q000517:prevention & control*; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000517:prevention & control*; D011759:Pyrrolidines / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*
D011759:Pyrrolidines; D020845:Selective Estrogen Receptor Modulators; D013764:Tetrahydronaphthalenes; C111332:Lasofoxifene